These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 28497847)

  • 1. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.
    Inno A; Metro G; Bironzo P; Grimaldi AM; Grego E; Di Nunno V; Picasso V; Massari F; Gori S
    Tumori; 2017 Sep; 103(5):405-421. PubMed ID: 28497847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
    Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
    Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events associated with immune checkpoint inhibitor treatment for cancer.
    Esfahani K; Meti N; Miller WH; Hudson M
    CMAJ; 2019 Jan; 191(2):E40-E46. PubMed ID: 30642824
    [No Abstract]   [Full Text] [Related]  

  • 5. Rare side-effects of checkpoint inhibitors.
    Kourie HR; Awada G; Awada AH
    Curr Opin Oncol; 2016 Jul; 28(4):295-305. PubMed ID: 27153354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM; Vryzaki E; Georgiou S
    Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitor-induced sarcoidosis-like granulomas.
    Rambhia PH; Reichert B; Scott JF; Feneran AN; Kazakov JA; Honda K; Koon H; Gerstenblith MR
    Int J Clin Oncol; 2019 Oct; 24(10):1171-1181. PubMed ID: 31321613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Blockade in Cancer Therapy.
    Postow MA; Callahan MK; Wolchok JD
    J Clin Oncol; 2015 Jun; 33(17):1974-82. PubMed ID: 25605845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New checkpoint inhibitors ride the immunotherapy tsunami.
    Mullard A
    Nat Rev Drug Discov; 2013 Jul; 12(7):489-92. PubMed ID: 23812256
    [No Abstract]   [Full Text] [Related]  

  • 10. [Toxicity of immune checkpoints inhibitors].
    Delaunay M; Caron P; Sibaud V; Godillot C; Collot S; Milia J; Prévot G; Mazières J
    Rev Mal Respir; 2018 Dec; 35(10):1028-1038. PubMed ID: 30213624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
    O'Kane GM; Labbé C; Doherty MK; Young K; Albaba H; Leighl NB
    Oncologist; 2017 Jan; 22(1):70-80. PubMed ID: 27534573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors.
    Levine O; Devji T; Xie F
    Hum Vaccin Immunother; 2017 Aug; 13(8):1765-1767. PubMed ID: 28481695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors.
    Haanen JB; Robert C
    Prog Tumor Res; 2015; 42():55-66. PubMed ID: 26382943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.
    Baraibar I; Melero I; Ponz-Sarvise M; Castanon E
    Drug Saf; 2019 Feb; 42(2):281-294. PubMed ID: 30649742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing immune checkpoint-blocking antibody side effects.
    Postow MA
    Am Soc Clin Oncol Educ Book; 2015; ():76-83. PubMed ID: 25993145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune modulation in cancer with antibodies.
    Page DB; Postow MA; Callahan MK; Allison JP; Wolchok JD
    Annu Rev Med; 2014; 65():185-202. PubMed ID: 24188664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity.
    Zhang JC; Chen WD; Alvarez JB; Jia K; Shi L; Wang Q; Zou N; He K; Zhu H
    Acta Pharmacol Sin; 2018 Nov; 39(11):1693-1698. PubMed ID: 29991709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rare heart risk found with checkpoint inhibitors.
    Printz C
    Cancer; 2017 May; 123(9):1483-1484. PubMed ID: 28430361
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.
    Braschi-Amirfarzan M; Tirumani SH; Hodi FS; Nishino M
    Korean J Radiol; 2017; 18(1):42-53. PubMed ID: 28096717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular and orbital side-effects of checkpoint inhibitors: a review article.
    Antoun J; Titah C; Cochereau I
    Curr Opin Oncol; 2016 Jul; 28(4):288-94. PubMed ID: 27136135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.